VLCC partners with Central Marine Fisheries Research Institute (CMFRI)
Bangalore, 23rd May, 2017: VLCC, a leader in beauty and wellness industry in India, today announced that it has signed a license agreement with the Central Marine Fisheries Research Institute (CMFRI), the premier Kochi-based marine research establishment of the Indian Council of Agricultural Research (ICAR), Government of India, for exclusive rights to manufacture, market and use Cadalmin™ Antihypercholesterolemic (Cadalmin™ ACe) extract. This marine algae based nutraceutical product has been developed after years of intensive research by CMFRI and has been found to be effective in combating dyslipidemia1 and obesity.
As perCMFRI’s research, Cadalmin™ Ace provides a unique blend of 100 per cent naturalmarine bioactive ingredients from selected seaweeds known for theirextraordinary medicinal properties, with an eco-friendly ‘green’technology.VLCC will have the exclusive rights to manufacture and marketCadalmin™ Ace nutraceutical. VLCC has GMP certified manufacturing facilities inIndia and Singapore.
Thisnutraceuticalthat has been developed by CMFRI after years of intensive researchand testing.The pre-clinical trial showed no test substance-related generalorgan or systemic toxicity following long term oral administration of CadalminTMACe.VLCC will be working closely with the CMFRI to source relevant seaweed andmanufacture the product as per CMFRI developed technology.
Speaking onthe signing of the agreement, Mrs. Vandana Luthra, Founder, VLCC said,“We are excited that we have received the CMFRI license for Cadalmin™ACe. Highcholesterol and obesity are lifestyle related diseases that are becomingincreasingly common across age groups and lead to many other health problems,including blood pressure, diabetes, and cardiovascular ailments. VLCC has beencommitted to fighting obesity for decades and Cadalmin™ACe, with its high levelof efficacy and no side effects, will be instrumental in our next stage offight against obesity. We are confident that it will be well received byconsumers in India and across other countries in the world. ”
Dr.AGopalakrishnan, Director,CMFRI, said “Cadalmin™Antihypercholesterolemic extract is the fourth in theseries of the nutraceutical products developed by the CMFRI. Bioactivepharmacophore leads from seaweeds were used to prepare the Cadalmin TMAcenutraceutical. It does not have any side effects as established bydetailed preclinical trials and is a natural remedy of obesity anddyslipidemia.”
1 Dyslipidemia is an abnormal amount of lipids(e.g.,triglycerides, cholesterol and/or fat phospholipids) in the blood.
VLCC hasbeen spreading awareness on anti-obesity and healthy living across the world,for decades. Through its extensive of products and services, it has beentransforming lives and helping its customers to get fit and feel moreconfident. VLCC’s Anti-Obesity campaign has evolved into a larger movement,which has gained momentum as a public health campaign. The brand had alsoestablished Orange Pledge,where people could enroll for their commitment to thecause. In November 2016, VLCC celebrated 15 years of Anti-Obesity Day with the‘Standup India’ campaign – a public awareness initiative that encourages peopleto be more active in their daily lives through the simple act of standing up.